Cargando…

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)

BACKGROUND: Reduced daily life physical activity (DLPA) in pulmonary arterial hypertension (PAH) contributes to a poor quality of life. RESEARCH QUESTION: Can actigraphy be used to assess changes in DLPA in patients with PAH receiving selexipag or placebo? STUDY DESIGN AND METHODS: Effect of Selexip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Luke S., Rosenkranz, Stephan, Frantz, Robert P., Hemnes, Anna R., Pfister, Thomas, Hsu Schmitz, Shu-Fang, Skåra, Hall, Humbert, Marc, Preston, Ioana R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians 2023
Materias:	Pulmonary Vascular: Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899640/ https://www.ncbi.nlm.nih.gov/pubmed/36089068 http://dx.doi.org/10.1016/j.chest.2022.08.2231

Ejemplares similares

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
por: Han, Yuchi, et al.
Publicado: (2018)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017)

Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
por: Varela, Daniel L, et al.
Publicado: (2018)

Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper
por: Abraham, Paul, et al.
Publicado: (2018)

Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension
por: Greiner, Sebastian, et al.
Publicado: (2018)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

CENTRAL AND PERIPHERAL VENOUS THROMBOSIS IN NON-MECHANICALLY VENTILATED SURVIVORS OF COVID-19
por: Nauka, Peter, et al.
Publicado: (2020)

ACUTE PULMONARY EMBOLISM AND MYOCARDIAL INJURY IN COVID-19 PATIENT
por: Alfaki, Musaab, et al.
Publicado: (2020)

ANTICOAGULATION AND COVID-19: A META-ANALYSIS
por: Ho, Kam Sing, et al.
Publicado: (2020)

PULMONARY EMBOLISM AND RIGHT HEART STRAIN PATTERN IN COVID-19: AN INCIDENTAL FINDING OR A PERSISTENT PATTERN?
por: Roomi, Sohaib, et al.
Publicado: (2020)

PHLEGMASIA CERULEA DOLENS: AN ATYPICAL COVID-19 PRESENTATION
por: Akkari, Riad, et al.
Publicado: (2020)

MASSIVE PULMONARY EMBOLISM TREATED WITH THROMBOLYSIS IN COVID-19: A CASE SERIES
por: Alarcon-Calderon, Amarilys, et al.
Publicado: (2020)

COVID-19-ASSOCIATED COAGULOPATHY AS A PRESENTATION OF CORONAVIRUS DISEASE 2019: A PATIENT PRESENTS WITH A LARGE STROKE, PULMONARY EMBOLISM, AND DVT
por: Ramanathan, Rudra, et al.
Publicado: (2020)

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase
por: DiNicolantonio, James J, et al.
Publicado: (2020)

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
por: Pagnesi, Matteo, et al.
Publicado: (2020)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial
por: Russell, Stuart, et al.
Publicado: (2019)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

COVID-19 AS A PRIMARY CAUSE OF PULMONARY ARTERIAL HYPERTENSION
por: RAVAL, ABHIJIT, et al.
Publicado: (2021)

SADDLE PULMONARY EMBOLISM WITH CRITICAL LIMB ISCHEMIA IN COVID-19
por: MAHGOUB, AHMED, et al.
Publicado: (2021)

UTILITY OF D-DIMER CUT-OFF POINT WITH VTE IN CRITICALLY ILL PATIENTS WITH COVID-19
por: ZHANG, RAINY, et al.
Publicado: (2021)

THROMOEMBOLIC DISEASE: ONE OF MANY COMMON POST-COVID-19 COMPLICATIONS COMING SOON TO AN EMERGENCY ROOM NEAR YOU
por: BAIRD, ANDREW, et al.
Publicado: (2021)

CASE REPORT OF A COVID-19 INFECTION AND THROMBOEMBOLISM IN A PATIENT WITH ULCERATIVE COLITIS ON TOFACITINIB
por: SOMPALLI, SREEJA, et al.
Publicado: (2021)

SICKLE CELL DISEASE AND COVID-19
por: HANNA, SANDRINE, et al.
Publicado: (2021)

HAS COVID-19 LOST STEAM? A RETROSPECTIVE STUDY ON THE INCIDENCE OF VTE IN PATIENTS WITH COVID-19 AT A LARGE TERTIARY CARE HOSPITAL
por: AMANZAI, ABASIN, et al.
Publicado: (2021)

INCIDENCE AND OUTCOME OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH COVID-19 (SARS-COV-2) INFECTION: A SINGLE CENTER STUDY
por: SAHA, ADITI, et al.
Publicado: (2021)

THE CLOT THICKENS: DOES THE JOHNSON & JOHNSON COVID-19 VACCINE INCREASE THE RISK OF THROMBUS IN A HYPERCOAGULABLE STATE?
por: RUTENBERG, DAVID, et al.
Publicado: (2021)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis
por: Slivnick, Jeremy, et al.
Publicado: (2022)

Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland
por: Stubbs, Harrison, et al.
Publicado: (2022)

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
por: Suzuki, Sho, et al.
Publicado: (2022)

DIFFERENCES IN CLINICAL CHARACTERISTICS, TREATMENT, AND OUTCOME OF PULMONARY EMBOLISM ACCORDING TO COVID-19 STATUS
por: KELTY, CATHERINE, et al.
Publicado: (2022)

PFIZER COVID-19 VACCINE CAUSES SHORTNESS OF BREATH IN A 24-YEAR-OLD PATIENT: A CASE REPORT
por: GEARGES, CHRISTINA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s89c6e2ese917jod1n68h5tr7a